| | |
Per share
|
| |
Total
|
| ||||||
Public offering price
|
| | | $ | 1.20 | | | | | $ | 6,000,000 | | |
承保折扣和佣金(1)(2)
|
| | | $ | 0.07 | | | | | $ | 360,000 | | |
未扣除费用的收益(2)
|
| | | $ | 1.13 | | | | | $ | 5,640,000 | | |
| | |
Page
|
| |||
Prospectus Summary
|
| | | | 1 | | |
Risk Factors
|
| | | | 11 | | |
有关前瞻性陈述的特别说明
|
| | | | 62 | | |
Use of Proceeds
|
| | | | 64 | | |
Dividend Policy
|
| | | | 65 | | |
Capitalization
|
| | | | 66 | | |
Dilution
|
| | | | 67 | | |
管理层对财务状况和经营成果的讨论和分析
|
| | | | 68 | | |
Business
|
| | | | 82 | | |
股本说明
|
| | | | 123 | | |
美国联邦所得税对非美国持有者的重大影响
|
| | | | 129 | | |
Underwriting
|
| | | | 133 | | |
Legal Matters
|
| | | | 141 | | |
Experts
|
| | | | 141 | | |
在哪里可以找到更多信息
|
| | | | 142 | | |
通过引用并入某些信息
|
| | | | 143 | | |
| | |
As of June 30, 2022
|
| | | | |||||||||
(千,不包括每股和每股金额)
|
| |
Actual
|
| |
Pro Forma
|
| | ||||||||
现金和现金等价物
|
| | | $ | 45,771 | | | | | $ | 51,161 | | | | ||
Stockholders’ equity | | | | | | | | | | | | | | | ||
普通股,每股面值0.001美元;2022年6月30日授权的250,000,000股;已发行和已发行的22,597,907股,实际;已发行和已发行的27,597,907股,预计
|
| | | | 22 | | | | | | 27 | | | | ||
新增实收资本
|
| | | | 147,671 | | | | | | 153,056 | | | | ||
Accumulated deficit
|
| | | | (103,594) | | | | | | (103,594) | | | | ||
累计其他综合损失
|
| | | | (200) | | | | | | (200) | | | | ||
股东权益总额
|
| | | $ | 43,899 | | | | | $ | 49,289 | | | | ||
Total capitalization
|
| | | $ | 43,899 | | | | | $ | 49,289 | | | |
|
每股公开发行价
|
| | | | | | | | | $ | 1.20 | | |
|
截至2022年6月30日的每股有形账面净值
|
| | | $ | 1.94 | | | | | | | | |
|
截至2022年6月30日每股有形账面净值下降,归因于
购买此产品的投资者 |
| | | | (0.16) | | | | | | | | |
|
本次发行生效后,截至2022年6月30日的调整后每股有形账面净值
|
| | | | | | | | | | 1.79 | | |
|
向参与此次发行的新投资者增加每股收益
|
| | | | | | | | | $ | 0.59 | | |
| | |
Six Months Ended
June 30, |
| | | | | | | |||||||||
(in thousands)
|
| |
2022
|
| |
2021
|
| |
Change
|
| |||||||||
合并报表数据: | | | | | | | | | | | | | | | | | | | |
Operating Expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 15,616 | | | | | $ | 9,324 | | | | | $ | 6,292 | | |
一般和行政
|
| | | | 6,010 | | | | | | 2,243 | | | | | | 3,767 | | |
总运营费用
|
| | | | 21,626 | | | | | | 11,567 | | | | | | 10,059 | | |
Loss from operations
|
| | | | (21,626) | | | | | | (11,567) | | | | | | (10,059) | | |
| | |
Six Months Ended
June 30, |
| | | | | | | |||||||||
(in thousands)
|
| |
2022
|
| |
2021
|
| |
Change
|
| |||||||||
Other income (expense): | | | | | | | | | | | | | | | | | | | |
Grant income
|
| | | | 12,289 | | | | | | 9,338 | | | | | | 2,951 | | |
衍生负债公允价值变动
|
| | | | — | | | | | | 2,209 | | | | | | (2,209) | | |
保险箱公允价值变动
|
| | | | — | | | | | | (1,044) | | | | | | 1,044 | | |
Other (expense) income, net
|
| | | | (237) | | | | | | 248 | | | | | | (485) | | |
债务清偿收益
|
| | | | — | | | | | | 443 | | | | | | (443) | | |
Interest expense, net
|
| | | | (16) | | | | | | (894) | | | | | | 878 | | |
Total other income, net
|
| | | | 12,036 | | | | | | 10,300 | | | | | | 1,736 | | |
Loss before income taxes
|
| | | | (9,590) | | | | | | (1,267) | | | | | | (8,323) | | |
Net loss
|
| | | $ | (9,590) | | | | | $ | (1,267) | | | | | $ | (8,323) | | |
|
| | |
Six Months Ended
June 30, |
| | | | | | | |||||||||
| | |
2022
|
| |
2021
|
| |
Change
|
| |||||||||
Clinical programs
|
| | | $ | 9,050 | | | | | $ | 1,684 | | | | | $ | 7,366 | | |
Personnel
|
| | | | 3,362 | | | | | | 1,936 | | | | | | 1,426 | | |
Manufacturing
|
| | | | 2,061 | | | | | | 4,719 | | | | | | (2,658) | | |
Preclinical programs
|
| | | | 1,036 | | | | | | 926 | | | | | | 110 | | |
设施和其他成本
|
| | | | 107 | | | | | | 59 | | | | | | 48 | | |
| | | | $ | 15,616 | | | | | $ | 9,324 | | | | | $ | 6,292 | | |
| | |
Year Ended
December 31, |
| | | | | | | |||||||||
(in thousands)
|
| |
2021
|
| |
2020
|
| |
Change
|
| |||||||||
合并报表数据: | | | | | | | | | | | | | | | | | | | |
Operating Expenses: | | | | | | | | | | | | | | | | | | | |
研发
|
| | | $ | 18,572 | | | | | $ | 12,887 | | | | | $ | 5,685 | | |
一般和行政
|
| | | | 10,026 | | | | | | 4,520 | | | | | | 5,506 | | |
总运营费用
|
| | | | 28,598 | | | | | | 17,407 | | | | | | 11,191 | | |
Loss from operations
|
| | | | (28,598) | | | | | | (17,407) | | | | | | (11,191) | | |
Other income (expense): | | | | | | | | | | | | | | | | | | | |
Grant income
|
| | | | 17,447 | | | | | | 10,855 | | | | | | 6,592 | | |
衍生负债公允价值变动
|
| | | | 2,209 | | | | | | 18 | | | | | | 2,191 | | |
权证负债的公允价值变动
|
| | | | — | | | | | | 181 | | | | | | (181) | | |
未来简易协议的公允价值变动
Equity |
| | | | (2,236) | | | | | | — | | | | | | (2,236) | | |
Other (expense) income, net
|
| | | | (88) | | | | | | 394 | | | | | | (482) | | |
债务清偿收益(亏损)
|
| | | | 443 | | | | | | (129) | | | | | | 572 | | |
Interest expense, net
|
| | | | (893) | | | | | | (1,751) | | | | | | 858 | | |
Total other income, net
|
| | | | 16,882 | | | | | | 9,568 | | | | | | 7,314 | | |
Net loss
|
| | | $ | (11,716) | | | | | $ | (7,839) | | | | | $ | (3,877) | | |
| | |
Year Ended
December 31, |
| | | | | | | |||||||||
| | |
2021
|
| |
2020
|
| |
Change
|
| |||||||||
Clinical programs
|
| | | $ | 4,679 | | | | | $ | 5,263 | | | | | $ | (584) | | |
Personnel
|
| | | | 4,882 | | | | | | 4,026 | | | | | | 856 | | |
Manufacturing
|
| | | | 7,465 | | | | | | 1,798 | | | | | | 5,667 | | |
Preclinical programs
|
| | | | 1,426 | | | | | | 1,693 | | | | | | (267) | | |
设施和其他成本
|
| | | | 120 | | | | | | 107 | | | | | | 13 | | |
| | | | $ | 18,572 | | | | | $ | 12,887 | | | | | $ | 5,685 | | |
| | |
Six Months Ended
June 30, |
| |||||||||
| | |
2022
|
| |
2021
|
| ||||||
经营活动使用的现金流
|
| | | $ | (8,345) | | | | | $ | (1,682) | | |
投资活动使用的现金流
|
| | | | (138) | | | | | | — | | |
融资活动提供的现金流(用于)
|
| | | | (465) | | | | | | 7,801 | | |
汇率变动对现金和现金等价物的影响
|
| | | | (2) | | | | | | (8) | | |
现金及现金等价物净(减)增
|
| | | $ | (8,950) | | | | | $ | 6,111 | | |
| | |
Less than
1 Year |
| |
1 to 3
Years |
| |
3 to 5
Years |
| |
More than 5
years |
| |
Total
|
| |||||||||||||||
经营租赁义务:
|
| | | $ | 149 | | | | | $ | 193 | | | | | $ | 170 | | | | | $ | 191 | | | | | $ | 703 | | |
Total:
|
| | | $ | 149 | | | | | $ | 193 | | | | | $ | 170 | | | | | $ | 191 | | | | | $ | 703 | | |
| | |
Kd (nM)
|
| |
B maxa
|
|
wt Aβ (1 – 42) oligomers
|
| | Site 1:442 ± 70 | | |
7.98 × 105 ± 0.29 × 105
|
|
A673T mutant Aβ (1 – 42) oligomers
|
| |
Site 1:1,955 ± 502
|
| |
5.98 × 105 ± 0.50 × 105
|
|
Funding Org
|
| |
Year
|
| |
Project
|
| |
Amount
|
| ||||||
国家老龄研究所(NIH)
|
| | | | 2016 | | | |
CT1812的COG0101 PH1b首次住院试验
|
| | | $ | 2,410,669 | | |
国家老龄研究所(NIH)
|
| | | | 2016 | | | | COG0102 Ph1b/2a Clinical Trial for CT1812 | | | | $ | 2,410,669 | | |
国家老龄研究所(NIH)
|
| | | | 2017 | | | | COG0104 PH1 SNAP研究:脑脊液导管 | | | | $ | 2,527,271 | | |
国家老龄研究所(NIH)
|
| | | | 2017 | | | | COG0105 Ph1 SPARC Study: SV2a PET | | | | $ | 4,795,774 | | |
国家老龄研究所(NIH)
|
| | | | 2018 | | | | COG0201 Ph2 SHINE Study | | | | $ | 16,848,329 | | |
国家老龄研究所(NIH)
|
| | | | 2019 | | | | COG0202 Ph2 SEQUEL Study: qEEG | | | | $ | 5,445,051 | | |
国家老龄研究所(NIH)
|
| | | | 2020 | | | | COG0203 Ph2 Study with ACTC | | | | $ | 80,974,766 | | |
国家老龄研究所(NIH)
|
| | | | 2021 | | | | COG0108 Study: hAME | | | | $ | 1,642,783 | | |
国家老龄研究所(NIH)
|
| | | | 2021 | | | | COG0201 Ph2 SHINE Amendment | | | | $ | 13,634,548 | | |
国家老龄研究所(NIH)
|
| | | | 2021 | | | | COG1201: Study: DLB | | | | $ | 29,498,048 | | |
NIH and others
|
| |
2010 – 2021
|
| | 十大临床前计划 | | | | $ | 10,859,971 | | | |||
| | | | | | | | | | | | | $ | 171,047,879 | | |
Underwriter
|
| |
Number of Shares
|
| |||
Cantor Fitzgerald & Co.
|
| | | | 4,500,000 | | |
新桥证券公司
|
| | | | 500,000 | | |
Total
|
| | | | 5,000,000 | | |
| | |
Per Share
|
| |
Total
|
| ||||||||||||||||||
| | |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| |
Without
Option to Purchase Additional Shares |
| |
With
Option to Purchase Additional Shares |
| ||||||||||||
Public offering price
|
| | | $ | 1.20 | | | | | $ | 1.20 | | | | | $ | 6,000,000 | | | | | $ | 6,900,000 | | |
承保折扣和佣金(6%)(1)
|
| | | $ | 0.07 | | | | | $ | 0.07 | | | | | $ | 360,000 | | | | | $ | 414,000 | | |
未扣除费用的收益给我们
|
| | | $ | 1.13 | | | | | $ | 1.13 | | | | | $ | 5,640,000 | | | | | $ | 6,486,000 | | |